Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Pharmacyclics LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: 607

Market Cap: -

Website: http://www.pharmacyclics.com

Clinical Trials

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia With 17p Deletion
Small Lymphocytic Lymphoma With 17p Deletion

Interventions: Drug: Ibrutinib

First Posted Date: 2012-12-07

Last Posted Date: 2017-02-27

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 145

Registration Number: NCT01744691

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Drug: Next-line ibrutinib

First Posted Date: 2012-11-09

Last Posted Date: 2023-09-21

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 232

Registration Number: NCT01724346

Locations: 🇺🇸
City of Hope /ID# 1116-0047, Duarte, California, United States
🇺🇸
Moores Cancer Center at UC San Diego /ID# 1116-0408, La Jolla, California, United States
🇺🇸
Stanford University/Stanford Cancer Center, Campus Drive /ID# 1116-0038, Stanford, California, United States

and more 85 locations

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Drug: Chlorambucil

First Posted Date: 2012-11-06

Last Posted Date: 2017-11-30

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 269

Registration Number: NCT01722487

Locations: 🇺🇸
Site Reference ID/Investigator #047, Duarte, California, United States
🇺🇸
Site Reference ID/Investigator #408, La Jolla, California, United States
🇺🇸
Site Reference ID/Investigator #720, Santa Rosa, California, United States

and more 105 locations

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: ofatumumab
Drug: ibrutinib

First Posted Date: 2012-04-17

Last Posted Date: 2019-12-18

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 391

Registration Number: NCT01578707

Locations: 🇺🇸
Site #408, La Jolla, California, United States
🇺🇸
Site #377, Los Angeles, California, United States
🇺🇸
Site #403, Santa Maria, California, United States

and more 73 locations

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: PCI-32765
Drug: Dexamethasone

First Posted Date: 2011-11-23

Last Posted Date: 2020-03-10

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 92

Registration Number: NCT01478581

Locations: 🇺🇸
SITE-13, La Jolla, California, United States
🇺🇸
SITE-5, Baltimore, Maryland, United States
🇺🇸
SITE-4, Boston, Massachusetts, United States

and more 8 locations

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large Cell B-lymphoma

Interventions: Drug: ibrutinib

First Posted Date: 2011-03-30

Last Posted Date: 2017-03-31

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 78

Registration Number: NCT01325701

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
National Cancer Institute, Bethesda, Maryland, United States

and more 12 locations

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Small Lymphocytic Lymphoma
B-cell Chronic Lymphocytic Leukemia

Interventions: Drug: PCI-32765

First Posted Date: 2011-02-09

Last Posted Date: 2014-07-24

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 33

Registration Number: NCT01292135

Locations: 🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
CLL Research and Treatment Program, New Hyde Park, New York, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

and more 3 locations

Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Phase 2

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: PCI-32765

First Posted Date: 2010-11-08

Last Posted Date: 2015-08-28

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 115

Registration Number: NCT01236391

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Cll Research and Treatment Program, New Hyde Park, New York, United States

and more 15 locations

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL

Phase 1

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Prolymphocyctic Leukemia
Richter's Transformation

Interventions: Drug: PCI-32765
Drug: ofatumumab

First Posted Date: 2010-10-08

Last Posted Date: 2015-06-25

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 71

Registration Number: NCT01217749

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Phase 1

Completed

Conditions: Lymphoma
Non-Hodgkin's Lymphoma
Hodgkin Disease
Multiple Myeloma
Leukemia
Lymphocytic

Interventions: Drug: PCI-24781

First Posted Date: 2010-06-23

Last Posted Date: 2013-06-19

Lead Sponsor: Pharmacyclics LLC.

Target Recruit Count: 7

Registration Number: NCT01149668

Locations: 🇺🇸
Northwestern Univ. Med School, Chicago, Illinois, United States
🇺🇸
Horizon Oncology Center, Lafayette, Indiana, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy